While ACHIEVE-3 shows clear superiority of orforglipron (12 mg / 36 mg) over oral semaglutide (7 mg / 14 mg) in T2D, its worth remembering that semaglutides newer 25 mg once-daily formulation (OASIS-4) for obesity has demonstrated ~15% mean weight reduction a very different efficacy profile than the earlier Rybelsus doses
[DOI] [PubMed] [Google Scholar] 62.Zhu Z., Zeng Q., Liu Q., Wen J., Chen G
Wasa J, Nishida Y, Tsukushi S, et al
Here, we review recent advances in our understanding of epigenetic regulation in neurogenesis and its dysregulation in brain disorders, including discussion of newly identified DNA cytosine modifications
If youre unsure how much protein you need, speak with a registered dietitian or healthcare professional
[1] [2] Protect from light and do not freeze